Cargando…
Ruxolitinib inhibits the proliferation and induces the apoptosis of MLL-r ALL cells through inactivating JAK/STAT signaling pathway
BACKGROUND: The childhood patients with mixed-lineage leukemia rearrangement (MLL-r) gene have worse outcome than non-MLL, and thus often treated with high-risk chemotherapy regimens, so targeted therapy is important for this type of leukemia. This purpose of study was to explore the effects of ruxo...
Autores principales: | Liao, Xiong-Yu, Zhou, Dun-Hua, Fang, Jian-Pei, Qiu, Kun-Yin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326758/ https://www.ncbi.nlm.nih.gov/pubmed/37427069 http://dx.doi.org/10.21037/tp-23-16 |
Ejemplares similares
-
The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019) -
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020) -
New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
por: Marcuzzi, Annalisa, et al.
Publicado: (2022) -
Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis
por: Li, Xia, et al.
Publicado: (2021) -
Fraxetin Inhibits the Proliferation and Metastasis of Glioma Cells by Inactivating JAK2/STAT3 Signaling
por: Qu, Liangchen, et al.
Publicado: (2021)